AcademicLabs Report on European Biotech Startups in Protein Degraders

Business Development-Weighted Landscape Assessment & Comparative Analysis

1. Introduction and Background

Targeted protein degradation, or TPD, has evolved from a niche chemical biology concept into a broad therapeutic strategy for eliminating disease-driving proteins rather than only inhibiting them. In the supplied company set, that evolution is visible in three distinct waves of innovation.

First, there is continued progress in more classical intracellular degrader approaches, including molecular glues and bifunctional degraders, but increasingly with efforts to move beyond the crowded CRBN and VHL landscape. Amphista is a strong example, positioning around non-CRBN/VHL Targeted Glue degraders and novel E3 ligases such as DCAF16 and FBXO22, with mechanistic support around DCAF16-mediated BRD9 degradation and near-clinical momentum for AMX-883 in AML (Amphista evidence, mechanistic publication, IND preparation). PhoreMost similarly represents the push toward more systematic molecular glue discovery and alternative E3 biology through GlueSEEKER and related platform outputs (PhoreMost evidence, platform abstract).

Second, the landscape is broadening beyond intracellular targets. Several profiles are compelling precisely because they extend degradation biology to extracellular, membrane-bound, or secreted targets. Laigo is advancing SureTAC bispecific antibodies for membrane-protein degradation (Laigo evidence); Draupnir is pursuing extracellular lysosomal routing using oral small molecules and sortilin-linked bifunctionals (Draupnir evidence, patent); GlycoEra is building bifunctional biologics for extracellular degradation in autoimmune disease (GlycoEra evidence).

Third, a subset of companies is testing non-canonical degradation architectures that may matter strategically if they prove translatable. Examples include Enodia with Sec61 or translocon-directed degradation at the point of synthesis (Enodia evidence); Booster with proteasome-stimulating Targeted Boosting Degraders, or Tarbods (Booster evidence); and Sibylla with folding-interference degraders via PPI-FIT (Sibylla evidence).

Business Development Framework: The objective of this report is not to identify the most academically interesting TPD startups in the abstract. It is to identify the companies most relevant for licensing, partnering, or acquisition by a pharma external innovation team. That requires balancing scientific novelty with practical actionability.

‍

Accordingly, this report applies an evidence-based and conservative lens. Scores and tiers reflect only the supplied materials. Where mechanistic publications, patents, translational datasets, regulatory interactions, funding syndicates, or partnership signals are visible, confidence increases. Where evidence is thin, abstract-level, or web-page-only, confidence is reduced explicitly. This distinction matters across the current set: a handful of companies now merit active business development outreach, a broader watchlist merits selective diligence, and a long tail should be deprioritized for this specific mandate despite occasional scientific interest.

The central conclusion from the portfolio is that the opportunity set is real but uneven. The most attractive near-term targets combine direct TPD relevance, differentiated modality positioning, credible validation, and visible execution momentum. The rest divide between promising but under-validated next-wave platforms and profiles that are adjacent, enabling, acquired, or insufficiently evidenced for present action.

2. Evaluation Framework and Scoring Legend

This report uses five key criteria applied through a BD-weighted lens aligned to licensing, partnering, and acquisition objectives.

2.1 Core Criteria

  • Deep expertise in developing and analyzing targeted protein degraders: Assesses whether the company shows clear TPD specialization, differentiated modality know-how, and evidence of technical depth in degrader discovery or analysis.
  • Validation of TPD technology: Assesses whether the supplied materials show meaningful mechanistic, cellular, in vivo, translational, or clinical evidence that the platform works.
  • Strength of scientific evidence: Assesses the quality and maturity of the evidence base, with peer-reviewed publications, mechanistic detail, reproducibility, and disclosed datasets weighted more heavily than company claims alone.
  • Momentum and progress: Assesses visible advancement such as candidate nomination, IND-enabling work, regulatory interactions, clinical plans, leadership build-out, or recent platform expansion.
  • Partnerships and funding: Assesses external validation through pharma partnerships, academic alliances, investor quality, grants, financing rounds, or strategic transactions.

2.2 Scoring Legend

All criteria are evaluated on a 1 to 10 scale:

  • 1 to 3 = Weak evidence for current BD actionability: Typically reflects limited evidence, indirect relevance, or lack of visible TPD-specific substantiation.
  • 4 to 5 = Mixed or early evidence: Potentially interesting, but key validation, scientific depth, or partnering proof is missing.
  • 6 to 7 = Credible and investable watchlist quality: Enough evidence to justify follow-up diligence, but not yet sufficiently de-risked for high-conviction action.
  • 8 to 10 = Strong current BD relevance: Clear TPD specialization, differentiated platform or asset quality, and visible progress supported by relatively strong evidence.

2.3 Contextual Breakdown of Scores

  • Expertise Score: Low means adjacent/service-oriented; High means differentiated degrader modality or clear ligase strategy.
  • Validation Score: Low means basic conceptual claims; High means mechanistic support, degradation data, or in vivo activity.
  • Science Score: Low indicates sparse disclosures or web-only data; High requires peer-reviewed publications or patent chemistry.
  • Momentum Score: Low indicates stagnation; High means candidate progression, IND-enabling stages, or clinical steps.
  • Partnerships & Funding Score: Low means minimal external backing; High means elite investor syndicates, grants, or active major pharmas.

2.4 Tiering Rules

  • Tier 1 = Highest-priority active BD targets now: Direct TPD relevance, differentiated strategy, visible momentum, and enough evidence to justify immediate outreach.
  • Tier 2 = Selective diligence and active watchlist: Credible and strategically interesting, but still constrained by evidence gaps, platform maturity, or unclear actionability.
  • Tier 3 = Deprioritize for the current mandate: Includes profiles that are adjacent rather than directly in TPD, primarily services/ecosystem entities, already acquired, or too weakly evidenced.

2.5 Strategic & Interpretation Notes

The comparative ranking incorporates a commercial transaction overlay. Highly novel science can be outranked by execution maturity or commercial independence. For example, Dark Blue is scientifically elite but deprioritized due to its acquisition by Amgen. Conversely, entities like Selvita and Ubiquigent are valuable technical enablers but function better as specialized CRO/service counterparties than independent therapeutic pipeline investments.

3. Comparative Ranking of the 33 Targeted Protein Degrader Companies

Ranking reflects BD-weighted attractiveness for licensing, partnering, or M&A in TPD, not raw science alone. Scale 1–10. (P/F = Partnerships / Funding; Avg = Simple Arithmetic Mean).

‍

‍

Top-Tier Rationale Summary

• Amphista Therapeutics (Rank 1, Avg 8.0): Strongest near-clinic small-molecule TPD story in the set: differentiated non-CRBN/VHL glues, mechanistic DCAF16 data, and AMX-883 moving toward IND.

• PhoreMost (Rank 2, Avg 7.8): High-value molecular glue platform with novel E3 biology and visible momentum; still mostly preclinical/platform-heavy.

• Beactica AB (Rank 3, Avg 7.4): Two credible degrader tracks (LSD1–CoREST, TEAD), regulatory progress on BEA-17, and meaningful external validation via NIH/NCATS and EIC funding.

• Laigo Bio (Rank 4, Avg 7.2): Differentiated membrane-protein degradation via SureTAC bispecifics, strong seed financing, and company-reported in vitro/in vivo efficacy; still preclinical.

• Draupnir Bio (Rank 5, Avg 6.6): Attractive extracellular TPD concept with Cell Chemical Biology visibility and IP support; breadth and depth of validation remain limited in the supplied materials.

• GlycoEra (Rank 6, Avg 6.4): Strong investor quality and differentiated extracellular degraders, but public scientific disclosure in the supplied set is thin relative to top-tier BD targets.

• Ternary Therapeutics (Rank 7, Avg 6.0): Early but credible molecular glue design story with AI/physics positioning and seed financing; key gap is partnerable validation data.

• Booster Therapeutics (Rank 8, Avg 6.0): Novel proteasome-stimulating 'Tarbod' thesis and solid early financing/IP, but evidence is still mostly patent/news based.

• Enodia Therapeutics (Rank 9, Avg 5.8): Non-canonical Sec61/translocon degradation approach is differentiated and the Kezar asset deal adds momentum, but current scientific proof is still limited.

• Kesmalea Therapeutics (Rank 10, Avg 5.0): Oral/CNS-penetrant degrader angle is strategically attractive, but validation, funding visibility, and disclosed data remain light.

• Ubiquigent (Rank 11, Avg 5.4): Strong UPS/DUB expertise and explicit DUBTAC/PROTAC relevance; ranked slightly lower because the supplied evidence supports a service/IP hybrid more than a de-risked startup asset story.

• Sibylla Biotech (Rank 12, Avg 4.8): Folding-interference degraders are genuinely differentiated, but public validation is still sparse and partnership/funding support is under-documented here.

• Proxygen (Rank 13, Avg 4.8): Explicit glue degrader focus is highly relevant, but the supplied dossier lacks recent publications/news/patents needed for higher conviction.

• TRIMTECH Therapeutics (Rank 14, Avg 5.2): Clear CNS aggregate-degrader positioning and meaningful seed funding, but still very data-light publicly.

4. Tiering of Profiles: Tier 1, Tier 2, and Tier 3

The tiering below translates the ranking and the underlying profile assessments into practical business development buckets.

Tier 1: Highest-Priority BD Targets Now

  • Amphista Therapeutics — Direct TPD relevance, distinctive clinical/preclinical validation pathways.
  • PhoreMost — Direct TPD relevance, distinctive clinical/preclinical validation pathways.
  • Beactica AB — Direct TPD relevance, distinctive clinical/preclinical validation pathways.
  • Laigo Bio — Direct TPD relevance, distinctive clinical/preclinical validation pathways.
  • Draupnir Bio — Direct TPD relevance, distinctive clinical/preclinical validation pathways.

Tier 2: Selective Diligence and Active Watchlist

GlycoEra, Ternary Therapeutics, Booster Therapeutics, Enodia Therapeutics, Kesmalea Therapeutics, Ubiquigent, Sibylla Biotech, Proxygen, TRIMTECH Therapeutics, Med Discovery, Selvita SA, Dunad Therapeutics Ltd

Tier 3: Deprioritize for the Stated Mandate

PROXIDRUGS - Cluster4Future, Dark Blue Therapeutics, GenProtex, LoQus23 Therapeutics Ltd, O2h Group, Outrun TX, RIANA Therapeutics, Orbit Discovery, Forschungsverbund Berlin, Tay Therapeutics, Vector BioPharma, DISCO Pharmaceuticals, Apeloa Pharmaceutical, Oxford Drug Design Limited, RDP Pharma AG, Stage Cell Therapeutics

4.2 Why the Tiers Differ in Practice

Tier 1 companies combine direct TPD relevance, unique ligase strategies, and near-term execution visibility. Amphista possesses the strongest near-clinic profile. PhoreMost scales industrial molecular glue discovery. Beactica offers flexible multi-indication oncology pipelines. Laigo addresses the membrane space, while Draupnir targets extracellular protein clearance via sortilin complexes.

Tier 2 profiles present strong scientific theses but are held back by limited public data, abstract-heavy disclosures, or pre-translational validation. Tier 3 includes entities that are structurally unaligned, such as Dark Blue (acquired by Amgen), or service providers like Selvita and O2h.

5. In-Depth Assessment of Tier 1 Profiles

5.1 Amphista Therapeutics

Score Profile — Exp: 9 | Val: 8 | Sci: 8 | Mom: 9 | P/F: 6 | Average: 8.0

‍

Amphista represents the most structurally complete platform-plus-asset candidate in the cohort. Operating via its proprietary Eclipsys platform, it successfully moves past crowded CRBN/VHL architectures into novel spaces like DCAF16 and FBXO22. Its lead clinical candidate, AMX-883, demonstrates robust oral in vivo activity in AML models and is currently entering IND-enabling sequences.

  • Deal Posture: Option-based platform-plus-asset collaboration or target-specific licensing setup.

5.2 PhoreMost

Score Profile — Exp: 9 | Val: 8 | Sci: 7 | Mom: 8 | P/F: 7 | Average: 7.8

‍

PhoreMost specializes in structural, non-serendipitous molecular glue screen deployment via its GlueSEEKER platform. Rather than screening classic cell lines blindly, the platform systematically creates novel E3-substrate pairings to reach historically undruggable nodes.

  • Deal Posture: Broad discovery engine access, target class option rights, and codevelopment structures.

5.3 Beactica AB

Score Profile — Exp: 8 | Val: 7 | Sci: 6 | Mom: 8 | P/F: 8 | Average: 7.4

‍

Beactica presents exceptional dual-track optionality with its lead program, BEA-17 (first-in-class LSD1-CoREST degrader), and a robust TEAD program targeting transcriptional oncology networks. Backed by solid non-dilutive EIC funding, it represents a highly actionable partner.

5.4 Laigo Bio

Score Profile — Exp: 8 | Val: 7 | Sci: 6 | Mom: 8 | P/F: 7 | Average: 7.2

‍

Laigo bridges the gap between traditional small-molecule degraders and biologics through its SureTAC bispecific antibodies. By coupling extracellular or cell-surface targets to native surface-bound E3 ligases, it achieves clean lysosomal clearance of membrane targets.

5.5 Draupnir Bio

Score Profile — Exp: 8 | Val: 7 | Sci: 6 | Mom: 8 | P/F: 4 | Average: 6.6

‍

Draupnir utilizes oral small-molecule macro-complexes linked to sortilin receptors to capture and clear extracellular/secreted proteins. While funding indicators appear light, its peer-reviewed validation makes it an essential early-access target.

6. Cross-Company Trends and Strategic Clusters

  • Moving Beyond CRBN and VHL: Amphista (DCAF16), PhoreMost, and Med Discovery (DCAF1) are leading the structural push into non-canonical ligases to circumvent tumor resistance pathways.
  • Extracellular & Membrane Expansion: Laigo, Draupnir, and GlycoEra are actively moving beyond traditional cytoplasmic constraints to expand the targetable proteome.
  • Non-Canonical Modalities: Booster (proteasome stimulation via Tarbods), Sibylla (folding-interference), and Enodia (nascent chain synthesis targeting at the translocon) mark high-risk, high-upside plays.

7. Strategic Recommendations & 90-Day Action Plan

  • Immediate Outreach: Initiate structured evaluations with the 5 Tier 1 targets using standardized diligence parameters.
  • Staged Commitments: Deploy milestone-dependent options and target-restricted evaluation structures to insulate pharma capital from early-stage translation risks.
  • Tier 2 Triggers: Monitor GlycoEra for scientific data transparency, Ternary for structural chemistry outputs, and Booster for proof beyond patent claims.

7.1 Suggested 90-Day Commercial Roadmap

  • Weeks 1-2: Establish value proposition profiles and draft custom outreach structures for Tier 1.
  • Weeks 3-6: Execute scientific introduction sequences and receive non-confidential validation materials.
  • Weeks 6-10: Open virtual data rooms for top-tier responsive names.
  • Weeks 10-12: Draft initial option term sheets or target-defined codevelopment master frameworks.

8. Executive Summary

The European targeted protein degradation ecosystem offers substantial innovation across intracellular glues, extracellular biologics, and non-canonical architectures, yet evidence remains polarized. Pharma external innovation teams must separate corporate narratives from decision-ready translational validation. Direct capital placement and active deal-making should immediately prioritize Tier 1 companies—specifically Amphista Therapeutics and PhoreMost—while systematically archiving and watchlisting Tier 2 assets via milestone-dependent tracking structures.

‍